Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa B Schrock

Showing results (1-10 of 130) with videos related to

Pageof 13
Sort By:
Experimental Hematology & Oncology|November 17, 2017
Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinomaShuyu D Li, Annia Martial, Alexa B Schrock, et al.
Lung Cancer (Auckland, N.Z.)|March 19, 2019
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with <i>EGFR</i>-mutant non-small cell lung cancer and emergent <i>MET</i> amplificationViola W Zhu, Alexa B Schrock, Siraj M Ali, et al.
Lung Cancer (Auckland, N.Z.)|December 20, 2017
<i>Cis</i>-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literatureSamuel J Klempner, Pareen Mehta, Alexa B Schrock, et al.
BMC Cancer|March 18, 2017
Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case reportMunveer S Bhangoo, Jenny Y Zhou, Siraj M Ali, et al.
Oncology|November 1, 2018
A Pan-Cancer Landscape Analysis Reveals a Subset of Endometrial Stromal and Pediatric Tumors Defined by Internal Tandem Duplications of BCORLuke T Juckett, Doug I Lin, Russell Madison, et al.
JTO Clinical and Research Reports|September 30, 2021
A Novel Sequentially Evolved <i>EML4-ALK</i> Variant 3 G1202R/S1206Y Double Mutation In <i>Cis</i> Confers Resistance to Lorlatinib: A Brief Report and Literature ReviewViola W Zhu, Misako Nagasaka, Russell Madison, et al.
JTO Clinical and Research Reports|September 5, 2022
A High Percentage of NSCLC With Germline <i>CHEK2</i> Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of LiteratureShannon S Zhang, Jessica K Lee, Hanna Tukachinsky, et al.
Lung Cancer (Amsterdam, Netherlands)|May 31, 2016
TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profilingViola Weijia Zhu, Daya Upadhyay, Alexa B Schrock, et al.
Lung Cancer (Auckland, N.Z.)|December 7, 2018
Dramatic response to alectinib in a lung cancer patient with a novel <i>VKORC1L1-ALK</i> fusion and an acquired ALK T1151K mutationViola W Zhu, Alexa B Schrock, Thangavijayan Bosemani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 8, 2023
Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-OsimertinibJulia K Rotow, Jessica K Lee, Russell W Madison, et al.
Pageof 13

Showing results (1-10 of 130) with videos related to

Sort By:
Pageof 13
Experimental Hematology & Oncology|November 17, 2017
Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinomaShuyu D Li, Annia Martial, Alexa B Schrock, et al.
Lung Cancer (Auckland, N.Z.)|March 19, 2019
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with <i>EGFR</i>-mutant non-small cell lung cancer and emergent <i>MET</i> amplificationViola W Zhu, Alexa B Schrock, Siraj M Ali, et al.
Lung Cancer (Auckland, N.Z.)|December 20, 2017
<i>Cis</i>-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literatureSamuel J Klempner, Pareen Mehta, Alexa B Schrock, et al.
BMC Cancer|March 18, 2017
Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case reportMunveer S Bhangoo, Jenny Y Zhou, Siraj M Ali, et al.
Oncology|November 1, 2018
A Pan-Cancer Landscape Analysis Reveals a Subset of Endometrial Stromal and Pediatric Tumors Defined by Internal Tandem Duplications of BCORLuke T Juckett, Doug I Lin, Russell Madison, et al.
JTO Clinical and Research Reports|September 30, 2021
A Novel Sequentially Evolved <i>EML4-ALK</i> Variant 3 G1202R/S1206Y Double Mutation In <i>Cis</i> Confers Resistance to Lorlatinib: A Brief Report and Literature ReviewViola W Zhu, Misako Nagasaka, Russell Madison, et al.
JTO Clinical and Research Reports|September 5, 2022
A High Percentage of NSCLC With Germline <i>CHEK2</i> Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of LiteratureShannon S Zhang, Jessica K Lee, Hanna Tukachinsky, et al.
Lung Cancer (Amsterdam, Netherlands)|May 31, 2016
TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profilingViola Weijia Zhu, Daya Upadhyay, Alexa B Schrock, et al.
Lung Cancer (Auckland, N.Z.)|December 7, 2018
Dramatic response to alectinib in a lung cancer patient with a novel <i>VKORC1L1-ALK</i> fusion and an acquired ALK T1151K mutationViola W Zhu, Alexa B Schrock, Thangavijayan Bosemani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 8, 2023
Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-OsimertinibJulia K Rotow, Jessica K Lee, Russell W Madison, et al.
Pageof 13